Related Experiment Video
Updated: Aug 13, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practice
1Cardiothoracic Centre, St Thomas' Hospital, London, UK.
Insights
The PROGRESS trial found that perindopril significantly reduces the risk of recurrent stroke, cardiovascular events, and heart failure in patients with a history of stroke or TIA. This blood pressure-lowering treatment is recommended for stable post-stroke patients.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke is a leading cause of death and disability.
- Survivors face a high risk of subsequent strokes within five years.
- Effective secondary prevention strategies are crucial.
Purpose of the Study:
- To evaluate the efficacy of blood pressure lowering with perindopril in preventing recurrent cerebrovascular and cardiovascular events.
- To assess the impact of perindopril on stroke, cardiovascular events, and heart failure in patients with a history of stroke or transient ischaemic attack (TIA).
Main Methods:
- The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a specific clinical trial.
- Investigated hypertensive and non-hypertensive patients with prior stroke or TIA.
- Assessed outcomes with perindopril-based treatment versus placebo.
Main Results:
- Perindopril significantly reduced the risk of stroke by 28%.
- Cardiovascular events were reduced by 26% with perindopril treatment.
- Heart failure incidence decreased by 26% in the perindopril group.
Conclusions:
- Perindopril offers significant benefits in secondary stroke prevention.
- Recommended for stable post-stroke patients, potentially combined with indapamide and other evidence-based treatments.
- Therapy initiation and monitoring can occur in outpatient or general practice settings.
Abstract:
Stroke is a major cause of morbidity and mortality. Those who survive have a one in six chance of a further stroke in the ensuing five years. The perindopril protection against recurrent stroke study (PROGRESS) is the first specific trial to address whether blood pressure lowering in hypertensive or non-hypertensive patients with a history of stroke or transient ischaemic attack (TIA) would reduce subsequent cerebrovascular and cardiovascular events. Results show that treatment based on perindopril significantly reduces stroke (28%), cardiovascular events (26%) and heart failure (26%). Stable patients post stroke should be considered for perindopril, and indapamide if possible, along with other evidence based risk reduction treatments (e.g. aspirin, statins). Therapy can be initiated and monitored either from hospital outpatients or general practice or both in co-operation.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

